

Application number

1393862

Type(s)

Word

Category

Trademark

CIPO Status

ABANDONED SECTION 40(3)

TM5 status

DEAD/APPLICATION/
Withdrawn/Abandoned



The owner of the trademark application withdrew (e.g. abandoned) the application and the application is no longer active.

Filed

2008-05-01

Applicant

Pfizer Inc.
235 East 42nd Street
New York, New York 10017
UNITED STATES OF
AMERICA

Agent

TORYS LLP
SUITE 3000
79 WELLINGTON ST. W.
BOX 270, TD CENTRE
TORONTO
ONTARIO M5K1N2

Documents

[View documents](#)

Index headings

STELTO

Goods (Nice class & Statement)

(1) Pharmaceutical preparations for the prevention and/or treatment of: cardiovascular disease; central nervous

Classification data

Disclaimer

The classification data is provided for information and searching purposes only. CIPO does not warrant the accuracy of the classes assigned to the trademark. This data has no legal value of any kind.

Claims

Proposed
Use in
CANADA

system diseases and disorders, namely central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, insomnia, mood disorders, bipolar disorder, seizure disorders, and smoking habits or addictions; neurological diseases and disorders, namely brain injury, spinal cord injury, seizure disorders, Alzheimer's, Huntington's disease, cerebral palsy, multiple sclerosis; genitourinary diseases and disorders, namely urological diseases, urological disorders, urinary incontinence, infertility, sexually transmitted diseases, inflammatory pelvic diseases, premature ejaculation; gastrointestinal diseases and disorders; musculoskeletal diseases and disorders, namely connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, fractures, sprains, cartilage injuries; allergies; diabetes; hypertension; erectile dysfunction; sexual dysfunction; metabolic diseases and disorders; hemolytic diseases and disorders; cancer; migraines; pain, namely headaches, migraines, back pain, pain from burns, neuropathic pain, post-herpetic neuralgia; chronic pain; fibromyalgia; obesity; inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; the respiratory system; infectious diseases, namely respiratory infections, eye infections; immunological diseases and disorders, namely autoimmune diseases, immunologic deficiency syndromes, HIV, Acquired Immune Deficiency Syndrome (AIDS); viral diseases and disorders, namely herpes, hepatitis, HIV, Acquired Immune Deficiency Syndrome (AIDS); stroke; psychiatric diseases and disorders, namely mood disorders, anxiety disorders, panic disorders, bipolar disorder, cognitive disorders, schizophrenia, depression; substance abuse disorders, namely alcoholism and drug addiction; carpal tunnel syndrome; varicose veins; dental and oral diseases; osteoporosis; arthritis; multiple sclerosis; yeast infections; prostate disorders; pulmonary disorders; sleep disorders, namely, insomnia and restless leg syndrome; premature ejaculation; macular degeneration; thrombosis; and thromboembolism; (2) pharmaceutical preparations for: use in oncology; dermatology, namely dermatitis, skin pigmentation diseases; ophthalmology; ocular disorders; gastroenterology; and gynecology; (3) pharmaceutical preparations, namely cholesterol preparations, namely

preparations to lower cholesterol; smoking cessation preparations; tissue and skin repair preparations; acne medication; allergy medication; antacids; anthelmintics; antiarrhythmics; antibiotics; anticoagulants; anticonvulsants; antidepressants; antiemetics; antiflatulants; antihistamines; antihypertensives; anti-infectives; anti-inflammatories; antiparasitics; antibacterials; antifungals; antivirals; burn relief medication; calcium channel blockers; central nervous system depressants; central nervous system stimulants; cough treatment medication; diarrhea medication; gastrointestinal medication; glaucoma agents; hydrocortisone; hypnotic agents; sedatives; and ophthalmic preparations.
5 - Pharmaceuticals and herbicides

Action History

Action	Action date	Due date	Comments
Filed	2008-05-01		
Created	2008-05-02		
Formalized	2008-05-05		
Search Recorded	2009-01-29		
Examiner's First Report	2009-01-29	2009-05-29	
Approval Notice Sent	2009-06-22	2009-07-20	
Approved	2009-08-13		APPROVED BY PROGRAM EX200M1
Advertised	2009-08-19		Vol.56 Issue 2860
Allowed	2009-12-04		
Allowance Notice Sent	2009-12-04	2011-05-01	
Extension of Time	2011-05-09	2011-11-01	Request Letter Date: 2011 /05/02
Extension of Time	2011-11-08	2012-05-01	Request Letter Date: 2011 /11/01
Rep for Service Changed	2012-04-30		From: 8390 To: 6258 / Voir Preuve au dossier /See evidence on File No. 1309785
Agent Changed	2012-04-30		From: 8390 To: 6258 / Voir Preuve au dossier /See evidence on File No. 1309785
Extension of Time	2012-05-10	2012-11-01	Request Letter Date: 2012 /05/01
Extension of Time	2012-11-01	2013-05-01	Request Letter Date: 2012 /10/25
Extension of Time	2013-05-01	2013-11-01	Request Letter Date: 2013 /04/25
Extension of Time	2013-11-04	2014-05-01	Request Letter Date: 2013 /10/24

Correspondence Created	2014-05-12	2014-11-01	
Abandoned - Subsection 40(3)	2014-11-19		